Menu
Sign In Search Podcasts Charts Entities Add Podcast API Pricing

Peter Loftus

👤 Person
9 appearances

Podcast Appearances

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Novo Nordisk, yesterday, the stock had the best session in about two and a half years.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Novo Nordisk, yesterday, the stock had the best session in about two and a half years.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right. All right, have you heard of this so-called miracle drug Ozempic?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right. All right, have you heard of this so-called miracle drug Ozempic?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Shares of Novo Nordisk plunging by the most on record today after disappointing data from its experimental obesity drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Shares of Novo Nordisk plunging by the most on record today after disappointing data from its experimental obesity drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Novo Nordisk, yesterday, the stock had the best session in about two and a half years.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Right. All right, have you heard of this so-called miracle drug Ozempic?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Shares of Novo Nordisk plunging by the most on record today after disappointing data from its experimental obesity drug.